Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand
Rationale Recently, a CDC advisory Committee on Immunization Practices identified a likely association between the 2 COVID-19 mRNA vaccines from Pfizer-BioNTech and Moderna and cases of myocarditis and pericarditis. For the cardiovascular system, 4863 adverse events (AEs) were reported from the Pfizer vaccine. Common findings observed with vaccines under study were tachycardia(16.41%), flushing (12.17%), hypertension (5.82%), hypotension (3.6%), and increased heart rate (9.03%). In this study we characterized, classified, evaluate the dynamic of cardiac function and ECG abnormality after the Pfizer vaccine injection.
This is a prospective cohort study. All participants aged 13-18 years old and above who visited the second dose Pfizer covid-19 vaccine injection to determine cardiac manifestation.
Methods for analyzing research data The data will be collected from students enrollment at Kong thabbok upatham changkol kho so tho bo school and Wachirathamsatit school. The participant's history, physical exam, and laboratory data will be reviewed and data will be extracted based on the case record form (CRF). All data will be stored securely and analyzed using the SPSS® Statistics Version 23 developed by IBM®. Data entry will be carried out using coding and verification. Quantitative data will be expressed as mean with standard deviation (SD) or median (IQR) and qualitative data will be presented as a number of observations with percentage (%). Descriptive statistics will be used to summarize the baseline values and demographic data.
All p-values will be derived using the 2-tailed testing, and statistical significance will be set at 0.05 probability. All the categorical variables will be analyzed using the chi-square (x2) or Fisher's exact test whichever is appropriate. Normality of the distribution will be tested for the continuous variable using the Kolmogorov- Smirnov test. All the variables with normal distributions will be compared using the independent t-test and will be reported as mean ± standard deviation (SD). The variables that do not pass the normality test will be compared by means of the Mann-Whitney U test and will be reported as the median and interquartile range (IQR).
調査の概要
詳細な説明
Data Collection Methods
- Participants' demographics will be collected at baseline using case record form.
- Laboratory tests include: at 3 clinical visits (Baseline, Day3, Day7 and Day 14 (optional if have cardiac manifestation) after 2nd dose of Pfizer COVID-19 vaccine) 2.1. Cardiac biomarker (Troponin-T, CK-MB) 2.2. Echocardiography 2.3. ECG (Electrocardiography)
After getting approval from the Ethics Committee and before the start of the trial, the study team informed the interesting participants about the study by invitation letter with ZOOM or line meeting. Informed consent printed to the parents who interested in this project and bring to the team investigator before enrollment. A contact address and phone number will be provided for the interesting participants to call for more information about the study.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
BAngkok、タイ、10400
- Faculty of Tropical Medicine
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Student age 13-18 who received 1st dose of pfizer COVID-19 vaccine from
- Kong thabbok upatham changkol kho so tho bo school
- Wachirathamsatit school
説明
Inclusion Criteria:
- Age 13-18 years old
- Both males and females
- Received 1st dose Pfizer COVID-19 vaccine injection
Exclusion Criteria:
- Unable to obtain written informed consent from the participants or their legal representatives
- History of cardiomyopathy, tuberculous pericarditis, and constrictive pericarditis
- Severe allergic reaction to COVID-19 vaccine
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at baseline
時間枠:Day 0
|
cardiac manifestation defined as sinus tachycardia, hypertension at baseline
|
Day 0
|
|
Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at day 3
時間枠:Day 3
|
cardiac manifestation defined as sinus tachycardia, hypertension at day 3
|
Day 3
|
|
Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at day 7
時間枠:Day 7
|
cardiac manifestation defined as sinus tachycardia, hypertension at day 7
|
Day 7
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at baseline
時間枠:Day 0
|
frequency (%) of participant with myocarditis at baseline
|
Day 0
|
|
Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at day 3
時間枠:Day 3
|
frequency (%) of participant with myocarditis at day 3
|
Day 3
|
|
Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at day 7
時間枠:Day 7
|
frequency (%) of participant with myocarditis at day 7
|
Day 7
|
|
Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at baseline
時間枠:Day 0
|
frequency (%) of participant with pericarditis at baseline
|
Day 0
|
|
Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at day 3
時間枠:Day 3
|
frequency (%) of participant with pericarditis at day 3
|
Day 3
|
|
Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at day 7
時間枠:Day 7
|
frequency (%) of participant with pericarditis at day 7
|
Day 7
|
|
Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at baseline
時間枠:Day 0
|
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at baseline
|
Day 0
|
|
Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at day 3
時間枠:Day 3
|
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at day 3
|
Day 3
|
|
Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at day 7
時間枠:Day 7
|
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at day 7
|
Day 7
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Chayasin Mansanguan, M.D.、Mahidol University
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- Cardiac and pfiizer
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。